Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

TabimorelinvsCJC-1295 (No DAC)

An investigational oral growth hormone secretagogue that stimulates GH release through ghrelin receptor activation, though development was discontinued due to drug interaction concerns.

A modified growth hormone-releasing hormone that boosts your body's natural GH pulses for better recovery, deeper sleep, and improved body composition.

Growth HormoneGrowth Hormone

At a Glance

Quick
comparison

Dose Range

Tabimorelin

100–500 mg

CJC-1295 (No DAC)

100–300 mcg

Frequency

Tabimorelin

Once daily

CJC-1295 (No DAC)

Once daily

Administration

Tabimorelin

Oral (capsule or solution)

CJC-1295 (No DAC)

Subcutaneous injection

Cycle Length

Tabimorelin

4-6 weeks

CJC-1295 (No DAC)

8-12 weeks

Onset Speed

Tabimorelin

Moderate (1-2 weeks)

CJC-1295 (No DAC)

Moderate (1-2 weeks)

Evidence Level

Tabimorelin

Moderate human trials (Phase 1-2)

CJC-1295 (No DAC)

Moderate human trials (Phase 1-2)

Efficacy

Benefit
ratings

Tabimorelin
CJC-1295 (No DAC)

Growth Hormone Stimulation

Tabimorelin85%
CJC-1295 (No DAC)0%

Convenience & Compliance

Tabimorelin90%
CJC-1295 (No DAC)0%

Selectivity & Safety Profile

Tabimorelin75%
CJC-1295 (No DAC)0%

GH Stimulation

Tabimorelin0%
CJC-1295 (No DAC)88%

Sleep Quality

Tabimorelin0%
CJC-1295 (No DAC)92%

Recovery Support

Tabimorelin0%
CJC-1295 (No DAC)85%

Technical Data

Compound
specifications

Tabimorelin

Molecular Formula

C32H40N4O3

Molecular Weight

528.7 g/mol

Half-Life

Several hours (exact human half-life not published; dose-dependent pharmacokinetics)

Bioavailability

Orally active with dose-dependent bioavailability (increases at higher doses)

CAS Number

193079-69-5

CJC-1295 (No DAC)

Molecular Formula

C152H252N44O42

Molecular Weight

3367.9 g/mol

Half-Life

30 minutes to 2 hours

Bioavailability

~100% (subcutaneous)

CAS Number

863288-34-0

Protocols

Dosing
tiers

Tabimorelin

CJC-1295 (No DAC)

starting

100 mcg

Once daily before bed

2-4 weeks

Start here to assess tolerance and response. Best taken before bed to align with natural GH release during sleep.

standard

100-150 mcg

1-2 times daily

8-12 weeks

Most effective protocol for general health benefits. Often combined with a GHRP like Ipamorelin for enhanced effects.

advanced

150-300 mcg

2-3 times daily

8-12 weeks

Higher dosing for experienced users seeking maximum GH stimulation. Always combined with a GHRP for synergistic effects.

Applications

Best
suited for

Tabimorelin

+Stimulates growth hormone release from the pituitary gland through ghrelin receptor activation

+Orally active—no injections required, making it convenient for daily use

+Dose-dependent growth hormone and IGF-1 elevation at therapeutic doses

+Does not significantly raise ACTH, cortisol, or prolactin at most doses, showing better selectivity than some competing GH-releasing peptides

+Well-tolerated in short-term human studies with generally mild adverse effects

CJC-1295 (No DAC)

Natural Growth Hormone Optimization

Perfect for those wanting to boost their body's own GH production rather than using synthetic growth hormone. Mimics the natural pulsatile release pattern your pituitary uses.

Workout Recovery and Muscle Building

Athletes and fitness enthusiasts use it to accelerate recovery between training sessions, support lean muscle development, and reduce body fat over time.

Sleep Quality Enhancement

Because GH is naturally released during deep sleep, many users report dramatically improved sleep quality with more vivid dreams and feeling more refreshed upon waking.

Anti-Aging and Vitality

As GH levels decline with age, CJC-1295 helps restore more youthful hormone patterns, potentially improving skin quality, energy levels, and overall well-being.

Synergistic Peptide Stacking

Designed to work hand-in-hand with GHRPs like Ipamorelin. When combined, these peptides amplify each other's effects for significantly greater GH release than either alone.

Safety Profile

Side
effects

Tabimorelin

Common

  • Headache
  • Nausea
  • Appetite stimulation
  • Dizziness
  • Dry mouth

Serious

  • Drug-drug interactions via CYP3A4 inhibition

CJC-1295 (No DAC)

Common

  • Injection site reactions
  • Flushing or warmth
  • Water retention
  • Increased appetite

Uncommon

  • Tingling or numbness
  • Headache

Serious

  • Allergic reaction

Research Status

Safety
& evidence

Tabimorelin

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Tabimorelin is an oral GHS-R agonist with preclinical and early clinical data indicating dose-dependent appetite stimulation (potentially problematic for weight-conscious users) and transient blood glucose elevation due to GH's insulin-antagonistic effects. No human safety database exists beyond Phase 1/2 studies—efficacy and long-term safety profile in humans remain incompletely characterized. Potential risks include carpal tunnel syndrome (documented with chronic GH therapy), arthralgias, and theoretical tumor growth acceleration, though these are extrapolated from GH physiology rather than directly observed in limited human exposure.

Contraindications

  • xActive or history of carcinomas (ghrelin receptor agonists may stimulate growth of certain tumors)
  • xConcurrent use of potent CYP3A4 substrates due to risk of dangerous drug-drug interactions
  • xUntreated thyroid dysfunction
  • xUncontrolled diabetes

CJC-1295 (No DAC)

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

CJC-1295 without DAC has been studied in Phase 1-2 human clinical trials with a favorable safety profile. The most common side effects are mild and include injection site reactions and temporary flushing. Because it stimulates natural GH release rather than providing exogenous GH, it maintains the body's feedback mechanisms.

Contraindications

  • xActive cancer or history of cancer
  • xPregnancy or breastfeeding
  • xPituitary tumors or disorders
  • xHypersensitivity to GHRH analogs
  • xDiabetic retinopathy

Decision Guide

Which is
right for you?

Choose Tabimorelin if...

  • Stimulating growth hormone production in healthy individuals
  • Exploring GH secretagogue mechanisms in research settings
  • Patients preferring oral administration over injections

Choose CJC-1295 (No DAC) if...

  • Increasing natural growth hormone levels
  • Building lean muscle mass
  • Improving sleep quality
  • Enhancing workout recovery